The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau PET uptake occurs at a later stage and age than amyloid Pet and is more closely associated with cognitive dysfunction than amyloid-PET.(442, 443)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“robust evidence indicates that cerebral Aβ accumulation is one of the earliest mechanistic alterations of the whole pathophysiological dynamic of AD (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, CSF and positron emission tomography longitudinal studies support the hypothetical pathophysiological model of AD for which amyloidosis proceeds, either promoting or being permissive to the spreading of tau pathology that is likely to drive disease clinical evolution (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several genetic data studies (306 autosomal dominant mutations plus the APP gene duplication and trisomy 21) and multimodal biomarker studies indicate that an imbalance between Aβ production and clearance plays a critical and early role in AD pathogenesis (104–106,113,114).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“A large amount of evidence also supports the hypothesis that cerebral Aβ deposition begins decades before AD clinical onset and prior to cortical spreading of tau pathology.”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 2×
“Among individuals with dementia, syndromic diagnoses followed established criteria for FTD syndromes (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), probable DLB (McKeith et al., 2017), and AlzCS (McKhann et al., 1984, 2011; Jack et al., 2018).”
BackgroundMethodSelf-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · cited 15×
“Participants were assigned a diagnosis of cognitively unimpaired (defined as not MCI or dementia), MCI (Petersen, 2004), or dementia (American Psychiatric Association, 1994) using established criteria.”
InfluentialSelf-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“Among individuals with dementia, syndromic diagnoses followed established criteria for FTD syndromes (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), probable DLB (McKeith et al.”
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 3×
“Amyloid PET imaging was performed with Pittsburgh Compound B (PIB) (Klunk et al., 2004) and tau PET with flortaucipir (Chien et al.”
Cited by
Items 101–200 of 206
A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline
Sun, Y., Wang, M., Zhao, Y., Hu, K., Liu, Y., Liu, B., & Initiative, A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215163 · Cited by 17
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
Shcherbinin, S., Morris, A., Higgins, I. A., Tunali, I., Lu, M., Deveau, C., Southekal, S. S., Kotari, V., Evans, C. D., Arora, A., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12415 · Cited by 18
Shimada, H., Minatani, S., Takeuchi, J., Takeda, A., Kawabe, J., Wada, Y., Mawatari, A., Watanabe, Y., Shimada, H., Higuchi, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124443 · Cited by 17
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K. N., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D., Prokop, S., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01581-2 · Cited by 16
Angelopoulou, E., Bougea, A. M., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2024) · Cells · doi:10.3390/cells13131164 · Cited by 17
“In this context, amyloid pathology has been suggested to be necessary for increased 3R/4R tau accumulation [46].”
BackgroundMoscoso, A., Grothe, M. J., Schöll, M., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05195-5 · Cited by 17
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies
Mak, E., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Raghavan, S., Vemuri, P., Jack, C. R., Min, H.-K. P., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00684-4 · Cited by 16
Self-citationMak, E., Reid, R. I., Przybelski, S. A., Fought, A. J., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Raghavan, S., Vemuri, P., Jack, C. R., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00944-x · Cited by 15
“PETimages were analyzed using our fully automated in-house image processing pipeline 103 .”
Self-citationHeston, M. B., Teague, J. P., Cody, K. A., Deming, Y. K., Chavez, E. R. D., Morse, J., Chin, N. A., Engelman, C. D., Chappell, R. J., Langhough, R. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70551 · Cited by 14
“7,54,55 While initially intuitive that high amyloid burden accelerates progression from T + to dementia, this is also somewhat counterintuitive because higher amyloid at T + translates to individuals having a longer A + to T + time.”
Yan, Y., Yang, Z., & Chen, L. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116876 · Cited by 16
Survey among experts on the future role of tau‐PET in clinical practice and trials
Vermeiren, M. R., Calandri, I. L., van der Flier, W. M., van de Giessen, E., & Ossenkoppele, R. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70033 · Cited by 14
Jiang, C., Wang, Q., Xie, S., Chen, Z., Fu, L., Peng, Q., Liang, Y., Guo, H., Guo, T., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac084 · Cited by 15
Correlation between Periodontitis and Onset of Alzheimer’s Disease: A Literature Review
Barbarisi, A., Visconti, V., Lauritano, D., Cremonini, F., Caccianiga, G., & Ceraulo, S. (2024) · Dentistry Journal · doi:10.3390/dj12100331 · Cited by 14
“Caution should be used to consider an abnormal Core 2 result as an indicator of the presence of a normal Core 1 result because abnormal amyloid PET (or a biofluid surrogate) is nearly always a prerequisite for neocortical AD tauopathy [29].”
BackgroundQin, Z., Wu, W., Yang, X., Wang, X., Ding, A., Huang, Y., Tang, J., Jiang, S., Zhang, P., Qian, C., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1592524 · Cited by 15
Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases
Krishnadas, N., Doré, V., Laws, S. M., Porter, T., Lamb, F., Bozinovski, S., Villemagne, V. L., & Rowe, C. C. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12326 · Cited by 13
The transformative potential of plasma phosphorylated tau
Jack, C. R. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30112-5 · Cited by 12
Self-citationProtocol Report on the Transcranial Photobiomodulation for Alzheimer’s Disease (TRAP-AD) Study
Iosifescu, D. V., Song, X., Gersten, M. B., Adib, A., Cho, Y., Collins, K. A., Yates, K. F., Puerto, A. M. H., McEachern, K. M., Osorio, R. S., et al. (2023) · Healthcare · doi:10.3390/healthcare11142017 · Cited by 12
“We will assess possible mediators of the treatment response including baseline tau burden (measured using Positron Emitting Topography [PET] with a 18F MK-6240 tracer), changes in measures of mitochondrial function (assessed using Phosphorus Magnetic Resonance Spectroscopic Imaging [31P-MRSI]), and blood flow in the p…”
BackgroundInfluentialGenetically identical twin-pair difference models support the amyloid cascade hypothesis
Coomans, E. M., Tomassen, J., Ossenkoppele, R., Tijms, B. M., Lorenzini, L., ten Kate, M., Collij, L. E., Heeman, F., Rikken, R. M., van der Landen, S. M., et al. (2023) · Brain · doi:10.1093/brain/awad077 · Cited by 12
“For example, whereas it is relatively common to observe amyloid-β pathology in the absence of neocortical tau pathology, it is rare to observe neocortical tau pathology in the absence of amyloid-β pathology.(8) However, although the amyloid cascade hy-”
BackgroundBhattarai, P., Taha, A., Soni, B., Thakuri, D. S., Ritter, E., & Chand, G. B. (2023) · Brain Informatics · doi:10.1186/s40708-023-00213-8 · Cited by 12
“Jack et al. [22] suggested that the shift from Aβ + /tau − to Aβ + /tau + is linked to severe cognitive decline; however, the connection between global/regional tau deposition topography and Aβ is still unknown [23].”
BackgroundAlzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Premenopausal bilateral oophorectomy and Alzheimer's disease imaging biomarkers later in life
Kantarci, K., Kapoor, E., Geske, J. R., Castillo, A. M., Fields, J. A., Kara, F., Knyazhanskaya, E. E., Schwarz, C. G., Senjem, M. L., Bailey, K. R., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14469 · Cited by 13
Self-citationOhno, M. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1161875 · Cited by 10
“The β-secretase BACE1, which initiates amyloid-β (Aβ) production, is a long-standing prime therapeutic target for Alzheimer’s disease (AD) based on solid evidence that Aβ increase is the first event driving subsequent pathological changes and cognitive symptoms (Hanseeuw et al., 2019; Jack et al., 2019).”
BackgroundLeiris, N. D., Perret, P., Lombardi, C., Gözel, B., Chierici, S., Millet, P., Debiossat, M., Bacot, S., Tournier, B. B., Chames, P., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04987-1 · Cited by 12
“…studies, particularly imaging studies in AD continuum, have identified a dynamic model in which Aβ lesions appear first and serve to trigger the propagation of Tau lesions from the mesial temporal lobe to the cortical regions, this being associated with the progression of cognitive symptoms [8, 9].”
BackgroundNeurobiological effects of music-making interventions for older adults: a systematic review
Espinosa, N., Schrire, Z. M., McKinnon, A. C., Almgren, H., Mowszowski, L., & Naismith, S. L. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03006-7 · Cited by 11
“Positron Emission Tomography (PET) studies have found that 55% and 27% of older adults who meet clinical criteria for MCI have evidence of Aβ deposition and pathological tau, respectively [16].”
Petersen, R. C., Graf, A., Atkins, A. S., Bryś, M., Murphy, J., Miller, D. S., Reyderman, L., Siemers, E., Smith, J. L., Carrillo, M. C., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70069 · Cited by 14
Self-citationRethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 9
Giuffrè, G. M., Quaranta, D., Citro, S., Morganti, T. G., Martellacci, N., Vita, M. G., Rossini, P. M., Calabresi, P., & Marra, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240150 · Cited by 8
Relationships between hypometabolism and both β‐amyloid and tau PET in corticobasal syndrome
Ghirelli, A., Goodrich, A. W., Stephens, Y. C., Graff‐Radford, J., Ali, F., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Agosta, F., Filippi, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70018 · Cited by 8
Self-citationHan, M., Frieg, B., Matthes, D., Leonov, A., Ryazanov, S., Giller, K., Nimerovsky, E., Stampolaki, Μ., Xue, K., Overkamp, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64443-6 · Cited by 11
Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data
Trudel, L., Therriault, J., Macedo, A. C., Hosseini, S. A., Arias, J. F., Chan, T., Rahmouni, N., Bezgin, G., Tissot, C., Woo, M. S., et al. (2026) · Brain · doi:10.1093/brain/awag018 · Cited by 10
Lu, S., Qiu, S., Yu, G., Zhang, A., & Zhao, Q. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103097 · Cited by 8
FibrilPaint to determine the length of Tau amyloids in fluids
Pedrola, J. A., Dekker, F. A., Garfagnini, T., Mayer, G., Koopman, M. B., Bergmeijer, M., Heesink, G., Rots, I., Claessens, M. M. A. E., Förster, F. G., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502847122 · Cited by 9
Buciuc, M., Duffy, J. R., Machulda, M. M., Graff-Radford, J., Pham, N. T. T., Martin, P. R., Senjem, M. L., Jack, C. R., Ertekin-Taner, N., Dickson, D. W., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012322 · Cited by 8
“48 used to define PiB-PET positivity.(25)”
Self-citationCSF phosphorylated tau as an indicator of subsequent tau accumulation
Cogswell, P. M., Wiste, H. J., Mielke, M. M., Schwarz, C. G., Weigand, S. D., Lowe, V. J., Therneau, T. M., Knopman, D. S., Graff‐Radford, J., Vemuri, P., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.02.015 · Cited by 8
Self-citationCoomans, E. M., van Tol, B. G. J., Groot, C., Smith, R. A., Palmqvist, S., Stomrud, E., Pontecorvo, M. J., Shcherbinin, S., Kennedy, I. A., Kotari, V., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07384-y · Cited by 8
Alterations of Audiovisual Integration in Alzheimer’s Disease
Liu, Y., Wang, Z., Wei, T., Zhou, S., Yin, Y., Mi, Y., Liu, X., & Tang, Y. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01125-7 · Cited by 8
“Enhanced audiovisual integration might cause hyperactivity of brain regions promote tau protein accumulation and increase hippocampal activation to subsequent Aβ deposition and bivariate amyloid and tau relationships clarifying the pathogenesis underlying cognitive decline [39, 97–99].”
BackgroundTau in dementia with Lewy bodies
Chin, K. S., Churilov, L. P., Doré, V., Villemagne, V. L., Rowe, C. C., Yassi, N., & Watson, R. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231177219 · Cited by 7
“In a previous positron emission tomography (PET) study using the first-generation tau tracer flortaucipir, the prevalence of tau PET positivity in DLB was 18% (Jack et al., 2019).”
BackgroundEngels, N., Koops, E. A., Hsieh, S., Wiklund, E. E., Schultz, A. P., Riphagen, J. M., Prokopiou, P. C., Hanseeuw, B. J., Rentz, D. M., Sperling, R. A., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01500-0 · Cited by 7
“Once NFTs are present in allocortical regions, beta-amyloid plaques can be robustly detected with positron emission tomography (PET) imaging [5, 6].”
Backgrounddos Santos, J. R., Catalão, C. H. R., Vulczak, A., Azzolini, A. E. C. S., & Alberici, L. C. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289388 · Cited by 6
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., Zhang, J., Chen, J., & Zheng, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05164-0 · Cited by 7
“Moreover, other studies found that the earliest pathological changes in AD appeared in the entorhinal region, where NFTs appeared in the absence of Aβ deposition [20–22].”
Aohara, K., Minatani, S., Kimura, H. M., Takeuchi, J., Takeda, A., Kawabe, J., Wada, Y., Mawatari, A., Watanabe, Y., Shimada, H., et al. (2019) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12366 · Cited by 6
Zhang, C., Tai, Y., Kong, M., Jia, P., Ma, G., Ba, M., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322196 · Cited by 5
“8 Thus, tau has become an attractive therapeutic target.”
The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study
Vermeiren, M. R., Somsen, J. F., Luurtsema, G., Reesink, F. E., Verwey, N. A., Hempenius, L., Tolboom, N., Biessels, G. J., Biesbroek, J. M., Vernooij, M. W., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01588-4 · Cited by 5
“By virtue of its higher accuracy for the diagnosis of symptomatic AD compared to amyloid-PET [11, 16, 27, 28, 31], we expect that the impact of tau-PET in clinical practice will be similar or even higher than that of amyloid-PET.”
Dickerson, B. C., & Atri, A. (2020) · PubMed · Cited by 7
Dynamic Aphasia as a Variant of Frontotemporal Dementia
Chandregowda, A., Clark, H. M., Duffy, J. R., Machulda, M. M., Lowe, V. J., Whitwell, J. L., & Josephs, K. A. (2021) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000289 · Cited by 5
Self-citationPatterns of pathological tau deposition reflect the dynamics of cortical brain activity
Han, F., Chen, X., Murphy, A., Lee, J., Ziontz, J., Landau, S. M., Baker, S. L., Harrison, T. M., & Jagust, W. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115853 · Cited by 4
Cody, K. A., Sokolowski, A., Johns, E., Guerra, L. M., Winer, J. R., Young, C. B., Younes, K., Dumitrescu, L. C., Archer, D. B., Durant, A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71017 · Cited by 4
“21,32,33 As amyloid and tau PET are increasingly being integrated into therapeutic trial design and clinical care, 17,34,35 characterizing this heterogeneity will be crucial for understanding and staging AD progression.”
Therriault, J., Gauthier, S. G., & Rosa‐Neto, P. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.52 · Cited by 4
PET and SPECT Imaging of Neurodegenerative Diseases
Drzezga, A. E., Bischof, G. N., Giehl, K., & van Eimeren, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00085-5 · Cited by 4
Connectome-Mediated Prediction of Future Tau-PET Burden in Alzheimer’s Disease
Damasceno, P. F., Joie, R. L., Shcherbinin, S., Southekal, S. S., Kotari, V., Higgins, I. A., Collins, E. C., Rabinovici, G. D., Mintun, M. A., & Raj, A. (2022) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280065 · Cited by 4
Tau positron emission tomography in tauopathies: A narrative review
Lee, H., Gu, Y., Seo, S. W., & Moon, S. H. (2023) · Precision and Future Medicine · doi:10.23838/pfm.2023.00016 · Cited by 4
Dominguez, P. A., Palpatzis, E., Akinci, M., Canal-García, A., Pereira, J. B., Bejanin, A., & Arenaza‐Urquijo, E. M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100294 · Cited by 4
“While cognitively unimpaired individuals can often present with a significant A β PET burden, it is less likely that they display an extensive pattern of tau-PET deposition [2].”
Wang, X., Ye, T., Zhou, W., Zhang, J., & Initiative, A. D. N. (2025) · Neurology · doi:10.1212/wnl.0000000000214041 · Cited by 4
Neurotheranostics: The Next Frontier for Health Span
Losee, M., Seibyl, J. P., & Kuo, P. H. (2023) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.265502 · Cited by 3
Ikari, Y., Akamatsu, G., Matsumoto, K., Yamane, T., Senda, M., & Fukuchi, K. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.267113 · Cited by 3
SPECT/PET Findings in Dementia with Lewy Bodies
Zabihi, S., Whitfield, T. J., & Walker, Z. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_17 · Cited by 3
PET Imaging of Amyloid and Tau in Alzheimer’s Disease
Okamura, N., & Harada, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_19 · Cited by 3
Dilcher, R., Malpas, C. B., O’Brien, W. T., McDonald, S. J., Despott, C., Bertram, K., Pase, M. P., Law, M., O'Brien, T. J., & Vivash, L. E. (2024) · medRxiv · doi:10.1101/2024.10.14.24315486 · Cited by 4
Asymmetric Amyloid-β Burden and Neurodegeneration in Late-Onset Alzheimer’s Disease Dementia
Lee, J., Kim, H. N., Kim, M. H., Shin, I. J., Lee, K., Kim, Y. S., Lee, S. M., & Moon, S. Y. (2021) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2021.3.15 · Cited by 2
Alzheimer’s Disease from Modeling to Mechanism Research
Sun, X., & Zhang, W. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_7 · Cited by 2
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: A Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110980 · Cited by 2
Effect of tau burden and Lewy pathology on neuropsychiatric symptoms in Aβ‐positive individuals
Kang, S., Ye, B. S., Yun, M. R., Lee, Y., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71116 · Cited by 2
Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals
Gordon, B. A., & Tijms, B. M. (2019) · Brain · doi:10.1093/brain/awz278 · Cited by 2
“In this issue of Brain, Jack and co-workers address these questions using amyloid-b and tau PET imaging in a cohort that includes healthy ageing participants as well as those with multiple dementing illnesses (Jack et al., 2019).”
BackgroundTau-PET Bildgebung der Demenzerkrankungen
Bischof, G. N. (2022) · Angewandte Nuklearmedizin · doi:10.1055/a-1712-6020 · Cited by 2
“Milde Kognitive Beeinträchtigung/MCI) von Patienten typische Anreicherungsmuster im Gehirn finden, die sich von den Mustern der Tau-Pathologie in anderen Tauopathien oder im Vergleich zu gesunden Kontrollen unterscheiden [3, 22].”
BackgroundTaha, A., Soni, B., Thakuri, D. S., Ritter, E., Bhattarai, P., & Chand, G. B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.25.509432 · Cited by 2
Global amyloid burden enhances network efficiency of tau propagation in the brain
Lauber, M. V., Bellitti, M., Kapadia, K., Jasodanand, V. H., Au, R., & Kolachalama, V. B. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241294084 · Cited by 5
“7,46,47 In terms of altered network connectivity between regions, our study highlights an interesting pattern consistent across the ADNI and A4 cohorts.”
Shekari, M., Escalante, A. G., Milà‐Alomà, M., Falcón, C., López‐Martos, D., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Niñerola‐Baizán, A., Ashton, N. J., Karikari, T. K., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.091448 · Cited by 1
Analytical considerations and clinical utility of plasma phosphorylated Tau217
Frykman, H. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2551648 · Cited by 1
Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy
Dilcher, R., Malpas, C. B., McDonald, S. J., O'Brien, W., Despott, C., Bertram, K., Pase, M. P., Frontzkowski, L. K., Law, M., O'Brien, T. J., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70327 · Cited by 1
Radiofrequency electromagnetic fields in Alzheimer’s therapy: emerging evidence and future prospects
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., & Zhang, J. (2026) · Electromagnetic Biology and Medicine · doi:10.1080/15368378.2026.2627962 · Cited by 1
“Some studies observe amyloid plaques prior to NFTs and neuronal loss (Thal et al. 2002; Buckner et al. 2005; Grothe et al. 2017), whereas others identify NFTs in the entorhinal cortex in the absence of Aβ deposition (Jack et al. 2017, 2019; Ossenkoppele et al. 2018).”
Rissanen, J.-A., Kärkkäinen, S., Katisko, K., Vanninen, A., Luikku, A. J., Rauramaa, T. H., Musialowicz, T., Kokki, M., Julkunen, V., Portaankorva, A. M., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261431800 · Cited by 1
“37,38 As pTau217 has previously been suggested as a marker of brain tau pathology, 19,20 elevated plasma pTau217 levels may indicate a risk of cognitive decline linked to brain tau pathology.”
McDade, E., Porsteinsson, A., Clifford, D. B., Llibre‐Guerra, J. J., Wang, G., Li, Y., Belyew, S., Mills, S., Santacruz, A., Supnet‐Bell, C., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00067-x · Cited by 1
Classification of tau status with machine learning models in amyloid‐positive cohorts
Lin, Y., Chiu, S.-C., Massey, R., Fang, Y.-H. D., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71683 · Cited by 1
Dhaynaut, M. (2019) · theses.fr (ABES) · doi:10.70675/54a412edzf72bz47b9zba9fz75b42cb07fcb · Cited by 1
Beyond the AJR: Tau PET, Amyloid PET, and MRI as Prognostic Markers in Early Alzheimer Disease
Kuo, P. H., & Zukotynski, K. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26836
Deramecourt, V. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.01.014 · Cited by 1
Chernyshova, E. V., Krutskikh, E. P., Babenkova, P. I., Nesterova, V. V., Pevzner, I. B., Plotnikov, E. Y., & Gureev, A. P. (2024) · Сорбционные и хроматографические процессы · doi:10.17308/sorpchrom.2024.24/12243
Imaging Markers of Amyloid and Tau in Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_20
Shekari, M., Escalante, A. G., Milà‐Alomà, M., Falcón, C., López‐Martos, D., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Niñerola‐Baizán, A., Ashton, N. J., Karikari, T. K., et al. (2025) · medRxiv · doi:10.1101/2025.07.09.25331011
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: a Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.111015 · Cited by 1
Dalton, M. A., D’Souza, A., Mahabadian, A. A., Calamante, F., & Piguet, O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.11.28.691222
“The EC is a key gateway for cortico-hippocampal communication, and degeneration of this pathway is thought to be a critical driver of memory decline in both normal ageing and Alzheimer’s disease (AD) (Jack et al., 2019; Maass et al., 2018).”
Additional file 1 of APOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., & Mormino, E. C. (2023) · Figshare · doi:10.6084/m9.figshare.22608413
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543276
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543279
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390786
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390792
Engels, N., Koops, E. A., Hsieh, S., Wiklund, E. E., Schultz, A. P., Riphagen, J. M., Prokopiou, P. C., Hanseeuw, B. J., Rentz, D. M., Sperling, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26054646
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543273
Cai, Y., Du, J., Li, A., Zhu, Y., Xu, L., Sun, K., Ma, S., & Guo, T. (2024) · Figshare · doi:10.6084/m9.figshare.26567042
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543264
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390795
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543267
Bullich, S., Mueller, A., De Santi, S., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390789
Williams, T., Bathe, T., Vo, Q., Sacilotto, P., McFarland, K. N., Ruiz, A. J., Hery, G. P., Sullivan, P. M., Borchelt, D. R., Prokop, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543261
Pelkmans, W., Ossenkoppele, R., Dicks, E., Strandberg, O., Barkhof, F., Tijms, B. M., Pereira, J. B., & Hansson, O. (2021) · Figshare · doi:10.6084/m9.figshare.15178725
La théorie d'Hétérochromatine dans le cadre de la maladie d'Alzheimer
Hogan, R. (2022) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/26044
Zhou, J. (2025) · eScholarship@McGill (McGill) · doi:10.82308/25089
A probabilistic Alzheimer's risk model based on Tau-PET SUVR for a patient subgroup
Tyagi, T., Salavudeen, A. H., Klebrowski, C., & Dey, J. (2026) · SPIE Medical Imaging: Physics of Medical Imaging · doi:10.1117/12.3087858
“A landmark bivariate analysis has demonstrated that Alzheimer’s pathology typically emerges first with amyloid deposition, followed by tau accumulation, with tau pathology showing stronger associations with cognitive decline and clinical symptoms [3].”
Subset stratification for predictive Alzheimer's models using Tau-PET SUVR
Salavudeen, A. H., Tyagi, T., Klebrowski, C., & Dey, J. (2026) · SPIE Medical Imaging: Physics of Medical Imaging · doi:10.1117/12.3087847
Thalamic nuclei insights into Alzheimer’s diseasePreprint
Vidal, J. P. C., Myall, D. J., Pariente, J., Pitcher, T. L., Roberts, R. P., Cawston, E. E., Heron, C. J. L., Anderson, T., Morgan, C., Melzer, T. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.728015
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., Kantarci, K., Lowe, V. J., Vemuri, P., Mielke, M. M., Fields, J. A., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology, Mayo Clinic, Rochester, MN, USA
- Corresponding author
- Jack, Clifford R
- ORCID
- Jack, Clifford R
- Wiste, Heather J
- Botha, Hugo
- Weigand, Stephen D
- Therneau, Terry M
- Knopman, David S
- Jones, David T
- Ferman, Tanis J
- Boeve, Bradley F
- Kantarci, Kejal
- Lowe, Val J
- Vemuri, Prashanthi
- Mielke, Michelle M
- Fields, Julie A
- Machulda, Mary M
- Schwarz, Christopher G
- Senjem, Matthew L
- Gunter, Jeffrey L
- Petersen, Ronald C
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-09
- Volume
- 142
- Issue
- 10
- Pages
- 3230-3242
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6763736
- OpenAlex
- W2972315303
- Cited by
- 200
- References
- 93
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 31 · 2023: 34 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 3
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R37 AG011378, RO1 AG041851, R01 AG056366, R01 NS097495, U01 AG06786, R01 AG034676, P50 AG016574)
- GHR Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- tau PET, amyloid-beta, bivariate distributions, mild cognitive impairment, frontotemporal dementia, dementia with Lewy bodies, Alzheimer's disease, tauopathy, amyloidosis, standardized uptake value ratio, cognitive aging, neurodegeneration biomarkers, Mayo Clinic Study of Aging, clinical syndromes
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloid, Amyloidosis, Brain, Cognition, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurocognitive Disorders, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.